You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Sleep and sleep conditions

Solriamfetol for treating excessive daytime sleepiness caused by narcolepsy

  • Technology appraisal guidance
  • Reference number: TA758
  • Published:  05 January 2022
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

On this page

  1. Expected publication
  2. Final draft guidance
  3. Draft guidance
  4. Invitation to participate

History

Documents created during the development process.

Expected publication

  • Equality Impact Assessment (Guidance development) (PDF 152 KB)

    Published:
    05 January 2022

Final draft guidance

  • Final draft guidance

  • Final appraisal document (PDF 258 KB)

    Published:
    18 November 2021
  • Public committee slides (PDF 884 KB)

    Published:
    18 November 2021
  • Committee papers (PDF 846 KB)

    Published:
    18 November 2021

Draft guidance

  • Draft guidance

  • Appraisal consultation document (PDF version) (PDF 265 KB)

    Published:
    05 March 2021
  • Appraisal consultation document (online commenting)

  • Committee papers (PDF 3.16 MB)

    Published:
    05 March 2021
  • Public committee slides (PDF 1.36 MB)

    Published:
    05 March 2021

Invitation to participate

  • Final scope (PDF 161 KB)

    Published:
    08 August 2019
  • Final stakeholder list (PDF 186 KB)

    Published:
    08 August 2019
  • Equality impact assessment (Scoping) (PDF 121 KB)

    Published:
    08 August 2019
  • NICE's response to comments on the draft scope and provisional stakeholder list (PDF 305 KB)

    Published:
    28 October 2019
Back to top